The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Hsp90 and Caveolin Are Key Targets for the Proangiogenic Nitric Oxide–Mediated Effects of Statins
Open accessAbstract
3-Hydroxy-3-methylglutaryl (HMG)–coenzyme A reductase inhibitors or statins exert direct beneficial effects on the endothelium in part through an increase in nitric oxide (NO) production. Here, we examined whether posttranslational modifications of the endothelial NO synthase (eNOS) could account for the proangiogenic effects of statins. We used endothelial cells (ECs) isolated from cardiac microvasculature, aorta, and umbilical veins, as well as dissected microvessels and aortic rings, that were cultured on reconstituted basement membrane matrix (Matrigel). Tube or precapillary formation was evaluated after statin treatment, in parallel with immunoblotting and immunoprecipitation experiments. Atorvastatin stimulated NO-dependent angiogenesis from both isolated and outgrowing (vessel-derived) ECs, independently of changes in eNOS expression. We found that in macro- but not microvascular ECs, atorvastatin stabilized tube formation through a decrease in caveolin abundance and its inhibitory interaction with eNOS. We also identified the chaperone protein hsp90 as a key target for the proangiogenic effects of statins. Using geldanamycin, an inhibitor of hsp90 function, and overexpression of recombinant hsp90, we documented that the statin-induced phosphorylation of eNOS on Ser1177 was directly dependent on the ability of hsp90 to recruit Akt in the eNOS complex. Finally, we showed that statin promoted the tyrosine phosphorylation of hsp90 and the direct interaction of hsp90 with Akt, which further potentiated the NO-dependent angiogenic processes. Our study provides new mechanistic insights into the NO-mediated angiogenic effects of statins and underscores the potential of these drugs and other modulators of hsp90 and caveolin abundance to promote neovascularization in disease states associated or not with atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kureishi, Y., Luo, Z., Shiojima, I., Bialik, A., Fulton, D., Lefer, D. J., Sessa, W. C., & Walsh, K. (2000) · Nature Medicine · doi:10.1038/79510 · Cited by 1,439
Current Perspectives on Statins
Maron, D. J., Fazio, S., & Linton, M. F. (2000) · Circulation · doi:10.1161/01.cir.101.2.207 · Cited by 1,213
Papapetropoulos, A., García-Cardeña, G., Madri, J. A., & Sessa, W. C. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119868 · Cited by 1,191
Modulation of Akt kinase activity by binding to Hsp90
Sato, S., Fujita, N., & Tsuruo, T. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.170276797 · Cited by 967
New insights into the pharmacodynamic and pharmacokinetic properties of statins
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00045-5 · Cited by 796
Fleming, I., Fisslthaler, B., Dimmeler, S., Kemp, B. E., & Busse, R. (2001) · Circulation Research · doi:10.1161/hh1101.092677 · Cited by 770
Bucci, M., Gratton, J.-P., Rudic, R. D., Acevedo, L., Roviezzo, F., Cirino, G., & Sessa, W. C. (2000) · Nature Medicine · doi:10.1038/82176 · Cited by 572
Michell, B. J., Chen, Z.-P., Tiganis, T., Stapleton, D., Katsis, F., Power, D. A., Sim, A. T., & Kemp, B. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100122200 · Cited by 560
Feron, O., Dessy, C., Desager, J.-P., & Balligand, J.-L. (2001) · Circulation · doi:10.1161/01.cir.103.1.113 · Cited by 417
Self-citationHarris, M. B., Ju, H., Venema, V. J., Liang, H., Zou, R., Michell, B. J., Chen, Z.-P., Kemp, B. E., & Venema, R. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100229200 · Cited by 363
Cited by
PLEIOTROPIC EFFECTS OF STATINS
Liao, J. K., & Laufs, U. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095748 · Cited by 1,994
Xu, S., Ilyas, I., Little, P. J., Li, H., Kamato, D., Zheng, X., Luo, S., Li, Z., Liu, P., Han, J., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000096 · Cited by 1,142
Role of Akt Signaling in Vascular Homeostasis and Angiogenesis
Shiojima, I., & Walsh, K. (2002) · Circulation Research · doi:10.1161/01.res.0000022200.71892.9f · Cited by 1,012
Sonveaux, P., Copetti, T., De Saedeleer, C. J., Végran, F., Verrax, J., Kennedy, K. M., Moon, E. J., Dhup, S., Danhier, P., Frérart, F., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033418 · Cited by 536
Self-citationStatin effects beyond lipid lowering—are they clinically relevant?
Bonetti, P. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00419-0 · Cited by 527
Balligand, J.-L., Feron, O., & Dessy, C. (2009) · Physiological Reviews · doi:10.1152/physrev.00042.2007 · Cited by 477
Self-citationPharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer
Gazzerro, P., Proto, M. C., Gangemi, G., Malfitano, A. M., Ciaglia, E., Pisanti, S., Santoro, A., Laezza, C., & Bifulco, M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004994 · Cited by 457
S. Antonopoulos, A., Margaritis, M., Lee, R., Channon, K., & Antoniades, C. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799504803 · Cited by 432
The critical role of Akt in cardiovascular function
Abeyrathna, P., & Su, Y. (2015) · Vascular Pharmacology · doi:10.1016/j.vph.2015.05.008 · Cited by 423
Nitric Oxide and the Vascular Endothelium
Moncada, S., & Higgs, E. A. (2006) · Handbook of Experimental Pharmacology · doi:10.1007/3-540-32967-6_7 · Cited by 408
Life history of eNOS: partners and pathways
DUDZINSKI, D., & MICHEL, T. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.03.023 · Cited by 400
Caveolin, Caveolae, and Endothelial Cell Function
Frank, P. G., Woodman, S. E., Park, D. S., & Lisanti, M. P. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000070546.16946.3a · Cited by 384
Thomas, S. R., Witting, P. K., & Drummond, G. R. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2027 · Cited by 383
“Studies with endothelial cells indicate that HMG-CoA reductase inhibitors can increase eNOS activity by increasing the enzyme expression (298), decreasing the binding of inhibitory caveolin-1 to eNOS (144), and enhancing PI3-K/Akt-dependent phosphorylation of the enzyme (281) that requires the recruitment of Hsp90 to…”
Fontana, J., Fulton, D., Chen, Y., Fairchild, T. A., McCabe, T. J., Fujita, N., Tsuruo, T., & Sessa, W. C. (2002) · Circulation Research · doi:10.1161/01.res.0000016837.26733.be · Cited by 344
van Nieuw Amerongen, G. P., Koolwijk, P., Versteilen, A., & van Hinsbergh, V. W. M. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000054198.68894.88 · Cited by 329
Caveolae and Caveolins in the Cardiovascular System
Gratton, J.-P., Bernatchez, P., & Sessa, W. C. (2004) · Circulation Research · doi:10.1161/01.res.0000129178.56294.17 · Cited by 317
Liao, J. K. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.009 · Cited by 304
Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer
Graaf, M. R., Richel, D. J., van Noorden, C. J. F., & Guchelaar, H.-J. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.06.010 · Cited by 300
The Role of Statins in Cancer Therapy
Hindler, K., Cleeland, C. S., Rivera, E., & Collard, C. D. (2006) · The Oncologist · doi:10.1634/theoncologist.11-3-306 · Cited by 291
Post-translational modifications of Hsp90 and their contributions to chaperone regulation
Mollapour, M., & Neckers, L. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.07.018 · Cited by 288
Cooke, J. P. (2003) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(03)00034-5 · Cited by 266
Higashi, Y., & Yoshizumi, M. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.02.003 · Cited by 262
Bell, R. M., & Yellon, D. M. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02816-4 · Cited by 261
Endothelial nitric oxide (NO) and its pathophysiologic regulation
Chatterjee, A., & Catravas, J. D. (2008) · Vascular Pharmacology · doi:10.1016/j.vph.2008.06.008 · Cited by 236
“It has been shown that hsp90-eNOS interaction is important for mediating the angiogenic reponse (Brouet et al., 2001).”
Background
Metadata
- Authors
- Brouet, A., Sonveaux, P., Dessy, C., Moniotte, S., Balligand, J.-L., & Feron, O.
- Venue
- Circulation Research
- Published
- 2001-11-09
- Volume
- 89
- Issue
- 10
- Pages
- 866-873
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2162975453
- Cited by
- 269
- References
- 19
- FWCI
- 6.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.